{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Lazzeroni M"],"pubmed_abstract":["Introduction
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare necrotizing vasculitis characterized by eosinophilic inflammation that was traditionally treated with corticosteroids associated with other immunosuppressants. Over the last years different biological therapies targeting IL-5/IL-5 receptor have become available and have been employed to tackle this challenging condition. Aim of the present study is to synthesis the evidence on the clinical presentation of this disease and on the efficacy of the newly available therapeutic strategies.Methods
In June 2024 PubMed, Embase and the Cochrane library were searched for studies reporting on EGPA patients being treated by means of different anti IL-5 or anti eosinophils biological therapies. Risk of bias was a"],"journal":["Frontiers in immunology"],"pagination":["1587158"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12321870"],"repository":["biostudies-literature"],"pubmed_title":["Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review."],"pmcid":["PMC12321870"],"pubmed_authors":["Gaffuri M","Lazzeroni M","Borin M","Gramellini G","Gidaro A","Lentini M","Mauro A","Schroeder J","Longoni V","Schiavo P","Dragonetti A","Maniaci A","Bizzi E","Brucato A","Capaccio P"],"additional_accession":[]},"is_claimable":false,"name":"Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review.","description":"Introduction
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare necrotizing vasculitis characterized by eosinophilic inflammation that was traditionally treated with corticosteroids associated with other immunosuppressants. Over the last years different biological therapies targeting IL-5/IL-5 receptor have become available and have been employed to tackle this challenging condition. Aim of the present study is to synthesis the evidence on the clinical presentation of this disease and on the efficacy of the newly available therapeutic strategies.Methods
In June 2024 PubMed, Embase and the Cochrane library were searched for studies reporting on EGPA patients being treated by means of different anti IL-5 or anti eosinophils biological therapies. Risk of bias was a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-03-31T11:47:57.804Z","creation":"2025-09-01T03:05:24.802Z"},"accession":"S-EPMC12321870","cross_references":{"pubmed":["40766318"],"doi":["10.3389/fimmu.2025.1587158"]}}